

# 1977: COSS

Cooperative Osteosarcoma Study Group



# COSS

COOPERATIVE OSTEOSARCOMA STUDY GROUP

---


- founded 1977, K. Winkler
- participants from D, A, CH (H, NL)
- neoadjuvant protocols since 1980




# COSS Infrastructure



# COSS Infrastructure



# COSS Infrastructure



# COSS Decision Making Processes



COSS

**COSS chairperson**  
**COSS study commission**

**GPOH board**

**GPOH assembly** (votes on chair q 5 years)

# COSS Infrastructure

COSS

## National Coordinators



Bielack, S.; Stuttgart



Kühne, Th., Basel



Papai, Z.; Budapest



Kager, L, Vienna



responsible for

*intra-country affairs:*

obtaining funds

regulatory approval/correspondence

ethics approval/correspondence

obtaining no-fault insurance

sponsorship contract

national pharmacovigilance obligations

organisation & funding of monitoring

other important business

contact to COSS-center

correspondence with CDC

finding rapid solutions for complicated problems

# COSS

## Recruitment Strategy

---

- **randomized trials**

- young patients with localized high-grade central extremity osteosarcoma

- **registry**

- young patients with localized high-grade central extremity osteosarcoma
- all other patients with conventional osteosarcoma
- osteosarcoma variants
- “biologically related” bone tumors

*(MFH, leiomyosarcoma of bone, dedifferentiated chondrosarcoma, ...)*

# GPOH-Studies

## Quality Assurance

- **interdisciplinary protocols**  
(local & systemic therapy; supportive care)
- **central review**
  - pathology
  - radiology
- **expert panel advises**
  - local therapy  
(surgery, irradiation)
  - chemotherapy

**EURO-B.O.S.S.**

**EURELOS / SAREZ**


Phase II

**EURAMOS**

**COSS Register**

# *COSS: 2464 patients 1980-2004*

## Recruitment by period



# German Ped. Oncology Multicenter Cooperation


GESELLSCHAFT FÜR  
PÄDIATRISCHE ONKOLOGIE  
UND HÄMATOLOGIE




Pädiatrische Onkologie  
und Hämatologie

## Therapy- Optimization Trials

=> therapeutic standard



# cross-Recruitment EURAMOS1

country		total	since	per year	of participation
• D		332	'05	ca. 70	
• CH		30	'05	ca. 6	
• H		19	'06	ca. 5	
• A		12	'08	ca. <u>6</u>	

87

# cross-Randomization EURAMOS1

country		total	since	per year	of participation
• D		219	'05	ca. 50	
• CH		20	'05	ca. 4	
• H		7	'06	ca. 3	
• A		14	'08	ca. 4	

61

# Funding



Deutsche  
Forschungsgemeinschaft

**DFG**



**ECT**  
**A EUROCORES PROGRAMME**

EUROPEAN SCIENCE FOUNDATION **COLLABORATIVE RESEARCH**



# Access to MTP on the market in DE (A, CH; H? CZ?)



# COSS: Recruitment / Randomization Projection

- Regulation etc.
  - => extremely tedious
  - => slow start? (international)
  - => loss of smaller institutions (medical oncology?)
- „upfront“ => higher randomization rate?
- additional countries?